142 related articles for article (PubMed ID: 23129464)
21. Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification.
Hashimoto H; Saito M; Kanda N; Yamamoto T; Mieno M; Hatakeyama S
BMC Pharmacol Toxicol; 2017 Nov; 18(1):74. PubMed ID: 29179737
[TBL] [Abstract][Full Text] [Related]
22. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
Ruggero MA; Peaper DR; Topal JE
Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
[TBL] [Abstract][Full Text] [Related]
23. During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.
Jonsson PI; Letertre L; Juliusson SJ; Gudmundsdottir BR; Francis CW; Onundarson PT
J Thromb Haemost; 2017 Jan; 15(1):131-139. PubMed ID: 27774726
[TBL] [Abstract][Full Text] [Related]
24. Real-world use of telavancin in the treatment of osteomyelitis.
Saravolatz LD; Cleveland KO; Rikabi K; Hassoun A; Reilly J; Johnson LB; Spak C; Valenti S; Szpunar S
Diagn Microbiol Infect Dis; 2019 Oct; 95(2):185-190. PubMed ID: 31256939
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA; Mavros MN; Vardakas KZ; Makris MC; Rafailidis PI; Falagas ME
PLoS One; 2012; 7(8):e41870. PubMed ID: 22916113
[TBL] [Abstract][Full Text] [Related]
26. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
Yamamoto R; Nakae Y; Tanaka F; Johkura K
J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
[TBL] [Abstract][Full Text] [Related]
27. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
28. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
Xiong YQ; Abdelhady W; Tang C'; Bayer AS
J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.
Marcos LA; Camins BC
Antimicrob Agents Chemother; 2010 Dec; 54(12):5376-8. PubMed ID: 20876369
[TBL] [Abstract][Full Text] [Related]
31. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Lunde CS; Hartouni SR; Janc JW; Mammen M; Humphrey PP; Benton BM
Antimicrob Agents Chemother; 2009 Aug; 53(8):3375-83. PubMed ID: 19470513
[TBL] [Abstract][Full Text] [Related]
32. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
33. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
34. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Kosowska-Shick K; Clark C; Pankuch GA; McGhee P; Dewasse B; Beachel L; Appelbaum PC
Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial Activity of Telavancin Tested
Duncan LR; Sader HS; Huband MD; Flamm RK; Mendes RE
Microb Drug Resist; 2020 Aug; 26(8):934-943. PubMed ID: 32049591
[TBL] [Abstract][Full Text] [Related]
36. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2928-33. PubMed ID: 19414568
[TBL] [Abstract][Full Text] [Related]
37. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
38. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
39. A new lipoglycopeptide: telavancin.
Nannini EC; Stryjewski ME
Expert Opin Pharmacother; 2008 Aug; 9(12):2197-207. PubMed ID: 18671473
[TBL] [Abstract][Full Text] [Related]
40. Coagulometer international sensitivity index (ISI) derivation, a rapid method using the prothrombin time/international normalized ratio (PT/INR) Line: a multicenter study.
Poller L; Ibrahim S; Jespersen J; Pattison A
J Thromb Haemost; 2012 Jul; 10(7):1379-84. PubMed ID: 22519939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
